HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Published online before print October 4, 2005

This Article Full Text (Reprint (PDF)) All Versions of this Article: jlb.0305172v1 78/6/1273    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thompson, B. S. Articles by Mitchell, T. C. Search for Related Content PubMed PubMed Citation Articles by Thompson, B. S. Articles by Mitchell, T. C.

© by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.0305172

Received for publication March 30, 2005.
Revised July 10, 2005.
Accepted for publication August 5, 2005.

Article

The low-toxicity versions of LPS, MPL® adjuvant and RC529, are efficient adjuvants for CD4⁺ T cells

Bruce S. Thompson ^*, Paula M. Chilton ^*, Jon R. Ward , Jay T. Evans , and Thomas C. Mitchell ^*@

*Institute for Cellular Therapeutics, Department of Microbiology and Immunology, University of Louisville, Kentucky; and The Corixa Corporation, Hamilton, Montana

^@ To whom correspondence should be addressed. E-mail: tom.mitchell{at}louisville.edu.

	Abstract

Lipopolysaccharide (LPS) has long been known to enhance innate and adaptive immune responses; however, its extreme toxicity precludes its use in clinical settings. The combined toxicity and adjuvanticity of LPS have contributed to the view that immunological adjuvants need to be highly inflammatory to be maximally effective. Here, we compared the effects of LPS with its less-toxic derivatives, monophosphoryl lipid A (MPL) and a chemical mimetic, RC529, on CD4⁺ T cell clonal expansion, long-term survival, and T helper cell type 1 (Th1) differentiation. We found that LPS, MPL, and RC529 had similar effects on CD4⁺ T cell clonal expansion, cell division, and ex vivo survival. Analysis of the ability of activated CD4⁺ T cells to produce interferon- following a 21-day immunization and challenge protocol with LPS and MPL resulted in similar Th1 differentiation. In contrast, we found that LPS was more effective in promoting long-term CD4⁺ T cell responses, as we recovered nearly sixfold more cells following immunization/challenge as compared with treatment with MPL. Our results indicate that low-inflammation adjuvants, such as MPL and RC529, are capable of enhancing short-term CD4⁺ T cell clonal expansion and Th1 differentiation, but inflammatory signaling aids in the long-term retention of antigen-specific T cells.

Key Words: AGP compounds • clonal expansion • T cell survival • mice • Toll-like receptors

This article has been cited by other articles:

				G. Hui, D. Choe, and C. Hashimoto Biological Activities of Anti-Merozoite Surface Protein-1 Antibodies Induced by Adjuvant-Assisted Immunizations in Mice with Different Immune Gene Knockouts Clin. Vaccine Immunol., August 1, 2008; 15(8): 1145 - 1150. [Abstract] [Full Text] [PDF]

				H. Shen, B. M. Tesar, W. E. Walker, and D. R. Goldstein Dual Signaling of MyD88 and TRIF Is Critical for Maximal TLR4-Induced Dendritic Cell Maturation J. Immunol., August 1, 2008; 181(3): 1849 - 1858. [Abstract] [Full Text] [PDF]